Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus
- 31 March 2005
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 149 (3) , 434-443
- https://doi.org/10.1016/j.ahj.2004.11.001
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)American Heart Journal, 2004
- Regression methods for covariate adjustment and subgroup analysis for non‐censored cost‐effectiveness dataHealth Economics, 2003
- PMI10 DANCING WITH THE DEVIL: THE IMPORTANCE OF SUB-GROUP ANALYSIS IN ECONOMIC EVALUATIONValue in Health, 2002
- Cost effectiveness of eptifibatide in acute coronary syndromes. An economic analysis of Western European patients enrolled in the PURSUIT trialPublished by Oxford University Press (OUP) ,2002
- Design, Analysis and Presentation of Multinational Economic StudiesPharmacoEconomics, 2002
- Cost Effectiveness of Bisoprolol in the Treatment of Chronic Congestive Heart Failure in SwedenPharmacoEconomics, 2001
- Cost Effectiveness in the Treatment of Heart Failure with RamiprilPharmacoEconomics, 1997
- Economic Evaluation Alongside Multinational Clinical Trials:Study Considerations for GUSTO iibInternational Journal of Technology Assessment in Health Care, 1997
- Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial InfarctionNew England Journal of Medicine, 1995
- Cost Effectiveness of Clinical Diagnosis, Venography, and Noninvasive Testing in Patients with Symptomatic Deep-Vein ThrombosisNew England Journal of Medicine, 1981